In Valeant Pharmaceuticals North America v. Mylan Pharmaceuticalsthe Federal Circuit clarified venue for Hatch-Waxman cases and addressed a split among district courts on where Abbreviated New Drug Application (ANDA) filers could be sued after TC Heartland. The Supreme Court in TC Heartland held that venue in patent infringement is only available where (1) the defendant is incorporated or (2) where it has a regular and established place of business and committed acts of infringement.